Delta-tocotrienol decreased biomarkers associated with fatty liver disease, says recent study
According to recent study, delta-tocotrienol from annatto decreased biomarkers associated with fatty liver disease in patients diagnosed with non-alcoholic fatty liver disease.
Photo © iStockphoto.com/nicolas_
In a new study published in Complementary Therapies in Medicine, delta-tocotrienol from annatto decreased biomarkers associated with fatty liver disease in patients diagnosed with non-alcoholic fatty liver disease (NAFLD).
The double-blind, active-controlstudy, conducted at the Armed Forces Institute of Pathology in Pakistan, randomly assigned 100 patients with NAFLD to receive either 300 mg twice daily of delta-tocotrienol or 268 mg twice daily of alpha-tocopherol for 48 weeks.
When compared with baseline, at 48 weeks, researchers saw a significant improvement in fatty liver index (FLI), liver-to-spleen attenuation ratio (L/S ratio), and homeostatic model assessment for insulin resistance (HOMA-IR) as well as serum malondialdehyde in both groups. There was a significant greater decrease in body weight, inflammation, and apoptosis in the delta-tocotrienol group compared to the alpha-tocopherol group.
“Thirty percent of the adult population worldwide has NAFLD, a tragedy the medical community refers to as ‘population code blue.’ This is the first time delta-tocotrienol was compared head-to-head with alpha-tocopherol, and the results did not disappoint,” said Barrie Tan, PhD, president of American River Nutrition, in a press release. American River Nutrition manufactures DeltaGold annatto-derived tocotrienol“Not only did delta-tocotrienol supplementation lead to superior sustained weight loss of > 10 pounds in obese NAFLD patients, but it was also significantly better at improving inflammation and preventing liver cell death than the alpha-tocopherol form of vitamin E commonly recommended by physicians. With the significant advantages of tocotrienol over tocopherol for weight loss and inflammation, the time has come to update the vitamin E guidance for NAFLD patients.”
Reference
- Pervez MA et al. “Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial.” Complementary Therapies in Medicine, Published online ahead of print on August 3, 2022, https://doi.org/10.1016/j.ctim.2022.102866
Microalgae extract supports metabolic health and bone mass during diet and exercise routine
April 11th 2024The extract from Microphyt, called PhaeOptim, was shown to complement weight management strategies that include diet and exercise by support bone mass, aerobic capacity, resting heart rate, and blood lipid profiles.
